Shanghai MicroPort EP MedTech's (SHA:688351) forecasts its attributable profit will rise 76% to 106% to between 30 million yuan and 35 million yuan in the first half from 17 million yuan in the prior-year period, according to a Wednesday filing with the Shanghai bourse.
Operating income at the medical device company is seen to grow 8.4% to 16% to between 215 million yuan and 230 million yuan during the half, from 198.4 million yuan in the year-ago period.
The upbeat forecast is attributable to steady growth in its overall sales volume following the launch of its TrueForce pressure monitoring radiofrequency ablation catheters, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。